GHRP-6: well-mapped pharmacology, unproven benefits

GHRP-6 is one of the oldest lab-made peptides designed to nudge the body into releasing growth hormone. The basics of what it does in people are genuinely well understood: it raises growth hormone (GH, a hormone that helps the body grow and repair tissue), and it makes people hungry. What is missing is the part that actually matters for the way it’s sold. For muscle growth, fat loss, anti-aging, or treating disease, there are no large, repeated human trials. And it has never been approved for any use, anywhere.

What it is

GHRP-6 is a small lab-made peptide built from six amino acids (the building blocks of proteins), strung together in the order His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The “D-form” amino acids were chosen on purpose to make the molecule sturdier and more powerful than the natural compound it was based on.

Here’s how it works. GHRP-6 is what scientists call a growth hormone secretagogue (a substance that prompts the body to release its own growth hormone), and it acts like ghrelin (the natural “hunger hormone”). It switches on a receptor called GHS-R1a, the same docking site ghrelin uses. Once switched on, that receptor sets off a chain of internal signals (involving an enzyme called phospholipase C and a release of calcium inside the cell) that pushes GH out of the pituitary gland (a small gland at the base of the brain that controls many hormones). This is a different route than the one used by GHRH (growth-hormone-releasing hormone, the body’s own main trigger for GH), though the two work well together. GHRP-6 matters in scientific history because peptides like it released GH through a receptor nobody had identified yet. That mystery is what led researchers to pin down the GHS-R1a receptor in 1996, and then, in 1999, to discover its natural partner, ghrelin.

One detail the marketing usually leaves out: in people, GHRP-6 is not a simple on/off “switch” for GH. Its effect on GH depends heavily on the body’s own GHRH still working. In one carefully controlled study, blocking GHRH cut the GH peak from about 33.8 down to 6.2 micrograms per liter. And because the GHS-R1a receptor also sits on the brain’s appetite-control neurons (in a region called the hypothalamus), GHRP-6 produces strong hunger. That hunger is its most reliable, most repeatable effect outside of GH.

The claims

On the gray market (the unregulated, unofficial channels where it’s bought and sold) and at some wellness clinics, GHRP-6 is pitched for muscle growth, fat loss, faster recovery, better sleep, “anti-aging,” and healing joints or tendons. The pitch usually runs like this: gently raise your GH, and you get the upsides of growth hormone without injecting GH directly. Separately, in legitimate research, it was once studied as a way to test how well a person’s body releases GH and as a possible treatment for people who don’t make enough of it. More recently, Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) has developed it as CIGB-500 to protect the heart after a heart attack and, paired with another molecule called epidermal growth factor, for sudden strokes caused by a blocked blood vessel.

The evidence

Here’s the honest split: the human pharmacology (how the drug behaves in the body) is real, but old and based on small studies, while the evidence that it actually helps patients is thin or missing entirely.

On how it works in the body and its short-term safety, the data are legitimate but modest. A 2013 study in nine healthy men looked at how the body processes a single dose given by IV. It found the drug spread through the body fast (a distribution half-life of roughly 7.6 minutes) and cleared out reasonably quickly (an elimination half-life of about 2.5 hours; a “half-life” is the time it takes for half of a dose to leave). A 1998 study, also in nine healthy men, showed that GHRP-6 needs the body’s own GHRH to do its job, because a drug that blocks GHRH wiped out most of the GH response. A 2014 study in 18 healthy men, which gradually raised the dose and was run by CIGB, reported an “acceptable safety profile” with no serious side effects, but it was small, knew who got the drug (open-label), and was run by the maker.

On whether it actually helps patients, the evidence falls short of what the claims suggest. The heart program (the AMIGOS study of CIGB-500 after a heart attack) is an early-stage, open-label trial aiming for about 20 patients, registered in 2014 with no results ever posted. The stroke research is a 2024 early-stage, unblinded (everyone knew who got what), randomized study in 36 patients that reported better survival and recovery scores. But it tested epidermal growth factor combined with GHRP-6, never GHRP-6 by itself, so you can’t credit the result to GHRP-6 alone. The authors themselves point out the small group and the unblinded design, and they call for a larger, more rigorous trial. The appetite effect, on the other hand, has solid backing from animal research, including a 2002 rat study showing GHRP-6 triggered eating through the brain’s appetite circuits.

What’s missing is the decisive part. There are no large, repeated, gold-standard trials (randomized controlled trials, where patients are randomly assigned and compared head-to-head) for any clinical outcome, and no efficacy program registered with the FDA or its European counterpart, the EMA. The modern efficacy work is run by the single Cuban maker that holds the patents, with no independent group confirming it, which is a warning sign about possible bias rather than proof. The popular bodybuilding and anti-aging claims have basically no controlled human outcome evidence behind them; they lean on the mechanism and on animal data. Even a 2017 review that gathered the case for GHRP-6 protecting cells was written mostly by that same Cuban group.

So the grade is Preliminary human: genuine small-scale human data on how it works and its safety do exist, plus a few early trials, but the human evidence stops well short of proving what GHRP-6 is actually sold for.

Safety and side effects

The most reliable effect is strong hunger, usually within about 20 to 30 minutes of a dose, driven by the same appetite neurons ghrelin acts on. On the hormone side, GHRP-6 is known for causing short-lived spikes in cortisol (the body’s main stress hormone) and prolactin (a hormone best known for its role in milk production). Those spikes make it less targeted to GH alone than newer compounds such as ipamorelin, and exactly how big those spikes get isn’t precisely pinned down here.

Short-term safety in the few available trials looked acceptable: the 18-person dose-escalation study reported no serious side effects, and the study on how the body processes the drug found no major safety warning signs. But these were small, brief studies. There’s no long-term human safety data at all. Some concerns that come with this whole class of drugs, including effects on insulin sensitivity and blood sugar, fluid retention, and the consequences of keeping GH high for a long time, simply haven’t been carefully studied for GHRP-6 specifically in people. The bottom line: long-term safety is unknown. None of this is medical advice.

There’s also a separate, real-world risk: product quality. Anything sold outside approved channels is unregulated, so there’s no way to confirm what’s actually in it or how pure it is.

Legal and regulatory status

GHRP-6 is not approved by the FDA, the EMA, or any major regulator for any use. It isn’t part of any approved drug, and it isn’t on the FDA’s 503A list of bulk substances that pharmacies are allowed to compound (mix into custom medications). In the FDA’s 2019 warning letter to United Pharmacy, the agency said GHRP-2 and GHRP-6 “were not nominated with adequate support for FDA to evaluate the substances,” and it flagged compounding with them as a violation. In plain terms, it can’t legally be compounded for patients or marketed for human use in the United States.

This is a fast-changing area. The FDA’s compounding rules were actively reworked in 2025 and 2026, including an April 2026 action that removed 12 peptides from Category 2 and scheduled an advisory-committee review. GHRP-6 wasn’t among those reclassified, but the status is worth checking again over time. Outside the US, there’s no general approval to use it as a treatment. The only active development is Cuba’s CIGB-500 program, still in early trials, which is not the same as being approved for sale.

In sport, the World Anti-Doping Agency bans GHRP-6 at all times, both in and out of competition, under Section S2.2.4 (“Growth hormone releasing factors”). The 2026 list names GHRP-6 by name alongside other GHRPs and GH secretagogues, and it uses “including, but not limited to” wording, so the ban doesn’t depend on the exact name. S2 substances are “non-specified,” which means they carry the strictest penalties.

Gray-market sellers usually label it “for research use only / not for human consumption.” That’s a legal fig leaf, not any kind of quality or safety guarantee.

Bottom line

GHRP-6 reliably raises growth hormone and reliably causes hunger in people, and that much is well documented, even if the studies are old and small. But for everything it’s actually marketed or being developed for, the human evidence is either missing or limited to tiny, mostly open-label, maker-run trials with no confirmed outcomes. It’s unapproved everywhere, has no legal compounding route in the US, has no established long-term safety record, and is banned in sport.

Evidence grade: 6/10 · Preliminary.

Sources

• Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
• Codd EE, Shu AY, Walker RF. Binding of the growth hormone releasing hexapeptide (SK&F 110679) to specific hypothalamic and pituitary binding sites. Neuropharmacology. 1989. PMID 2812284.
• Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996. PMID 8688086.
• Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.
• Cabrales A, et al. Pharmacokinetic study of growth hormone-releasing peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46. PMID 23099431.
• Selman-Housein KH, et al. Clinical safety study of CIGB-500 (GHRP-6) in healthy volunteers. Investigaciones Medicoquirúrgicas. 2014.
• Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. PMID 11751604.
• AMIGOS / CIGB-500 cardioprotection trial in acute myocardial infarction — Cuban Public Registry of Clinical Trials RPCEC00000177.
• Hernández-Bernal F, García-del-Barco-Herrera D, et al. EGF combined with GHRP-6 in acute ischemic stroke: a Phase I/II trial. Front Neurol. 2024;15:1303402.
• Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017.
• World Anti-Doping Agency — The Prohibited List.
• World Anti-Doping Agency — 2026 Prohibited List (PDF; S2.2.4 growth hormone releasing factors).
• Drugs.com — WADA S2: Peptide Hormones, Growth Factors, and Related Substances.
• FDA Warning Letter — United Pharmacy (Feb 11, 2019; cites GHRP-6 and GHRP-2).